SCHEMBL3019256

SCHEMBL3019256

COc1ccccc1Cc1csc(N2CCC(S(=O)(=O)c3ccc(OC)c(OC)c3)CC2)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.39
MAPK1 P28482 2/20 0.39
HSD17B10 Q99714 2/20 0.39
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
GLA P06280 1/20 0.39
TP53 P04637 1/20 0.39
HSD11B1 P28845 1/20 0.38
ADRA1A P35348 3/20 0.38
ADRA1B P35368 3/20 0.38
KDM4E B2RXH2 3/20 0.38
MAPT P10636 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 1/20 0.37
DRD2 P14416 1/20 0.37
ADRA1D P25100 1/20 0.37
HTR7 P34969 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3003521 0.93 TSHR (0.41) TSHRMAPK1HSD17B10USP2LMNA
SCHEMBL3018670 0.90 KCNA5 (0.38) TSHRHSD17B10USP2LMNAKDM4E
SCHEMBL3017438 0.90 KDM4E (0.43) TSHRHSD17B10USP2LMNAGLA
SCHEMBL3019118 0.90 MAPT (0.41) MAPK1HSD17B10USP2LMNATP53
SCHEMBL3015070 0.90 GBA1 (0.43) TSHRMAPK1USP2LMNATP53
SCHEMBL3006479 0.90 MAPT (0.40) LMNAKDM4EMAPTNPC1RAB9A
SCHEMBL3009492 0.90 POLB (0.41) TSHRMAPK1HSD17B10USP2LMNA
SCHEMBL3017841 0.90 POLB (0.42) TSHRHSD17B10USP2TP53HSD11B1
SCHEMBL3020230 0.89 KDM4E (0.42) HSD17B10USP2LMNAGLAKDM4E
SCHEMBL3011644 0.89 MAPT (0.36) HSD17B10KDM4EMAPTALDH1A1DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA TSHR 3320/4885MAPK1 2767/4885HSD17B10 2553/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.